Literature DB >> 18252896

Exendin-4 protects beta-cells from interleukin-1 beta-induced apoptosis by interfering with the c-Jun NH2-terminal kinase pathway.

Mourad Ferdaoussi1, Saida Abdelli, Jiang-Yan Yang, Marion Cornu, Guy Niederhauser, Dimitri Favre, Christian Widmann, Romano Regazzi, Bernard Thorens, Gérard Waeber, Amar Abderrahmani.   

Abstract

OBJECTIVE: The pro-inflammatory cytokine interleukin-1 beta (IL-1 beta) generates pancreatic beta-cells apoptosis mainly through activation of the c-Jun NH(2)-terminal kinase (JNK) pathway. This study was designed to investigate whether the long-acting agonist of the hormone glucagon-like peptide 1 (GLP-1) receptor exendin-4 (ex-4), which mediates protective effects against cytokine-induced beta-cell apoptosis, could interfere with the JNK pathway. RESEARCH DESIGN AND METHODS: Isolated human, rat, and mouse islets and the rat insulin-secreting INS-1E cells were incubated with ex-4 in the presence or absence of IL-1 beta. JNK activity was assessed by solid-phase JNK kinase assay and quantification of c-Jun expression. Cell apoptosis was determined by scoring cells displaying pycnotic nuclei.
RESULTS: Ex-4 inhibited induction of the JNK pathway elicited by IL-1 beta. This effect was mimicked with the use of cAMP-raising agents isobutylmethylxanthine and forskolin and required activation of the protein kinase A. Inhibition of the JNK pathway by ex-4 or IBMX and forskolin was concomitant with a rise in the levels of islet-brain 1 (IB1), a potent blocker of the stress-induced JNK pathway. In fact, ex-4 as well as IBMX and forskolin induced expression of IB1 at the promoter level through cAMP response element binding transcription factor 1. Suppression of IB1 levels with the use of RNA interference strategy impaired the protective effects of ex-4 against apoptosis induced by IL-1 beta.
CONCLUSIONS: The data establish the requirement of IB1 in the protective action of ex-4 against apoptosis elicited by IL-1 beta and highlight the GLP-1 mimetics as new potent inhibitors of the JNK signaling induced by cytokines.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18252896     DOI: 10.2337/db07-1214

Source DB:  PubMed          Journal:  Diabetes        ISSN: 0012-1797            Impact factor:   9.461


  54 in total

1.  Reduction of both beta cell death and alpha cell proliferation by dipeptidyl peptidase-4 inhibition in a streptozotocin-induced model of diabetes in mice.

Authors:  Y Takeda; Y Fujita; J Honjo; T Yanagimachi; H Sakagami; Y Takiyama; Y Makino; A Abiko; T J Kieffer; M Haneda
Journal:  Diabetologia       Date:  2011-11-10       Impact factor: 10.122

2.  Exendin-4 protects pancreatic beta cells from palmitate-induced apoptosis by interfering with GPR40 and the MKK4/7 stress kinase signalling pathway.

Authors:  Annalisa Natalicchio; Rossella Labarbuta; Federica Tortosa; Giuseppina Biondi; Nicola Marrano; Alessandro Peschechera; Emanuele Carchia; Maura Roberta Orlando; Anna Leonardini; Angelo Cignarelli; Piero Marchetti; Sebastio Perrini; Luigi Laviola; Francesco Giorgino
Journal:  Diabetologia       Date:  2013-08-31       Impact factor: 10.122

3.  A noncytolytic antibody-like extendin-4-IgG4 fusion protein as a long-acting potential anti-diabetic agent.

Authors:  Xiaoxia Li; Pinliang Hu; Rungong Yang; Jie Bai; Xingheng Wang; Shuhong Fu; Siyi Yang; Jinwei Ma; Meiliang Gong; Hong Chen; Feng Zhou; Yanbing Chen; Qian Zhou
Journal:  Int J Clin Exp Med       Date:  2015-03-15

Review 4.  Role of Wnt signaling pathways in type 2 diabetes mellitus.

Authors:  Jing Chen; Chong Ning; Jingjing Mu; Dongnan Li; Yan Ma; Xianjun Meng
Journal:  Mol Cell Biochem       Date:  2021-02-10       Impact factor: 3.396

5.  An anti-diabetes agent protects the mouse brain from defective insulin signaling caused by Alzheimer's disease- associated Aβ oligomers.

Authors:  Theresa R Bomfim; Leticia Forny-Germano; Luciana B Sathler; Jordano Brito-Moreira; Jean-Christophe Houzel; Helena Decker; Michael A Silverman; Hala Kazi; Helen M Melo; Paula L McClean; Christian Holscher; Steven E Arnold; Konrad Talbot; William L Klein; Douglas P Munoz; Sergio T Ferreira; Fernanda G De Felice
Journal:  J Clin Invest       Date:  2012-04       Impact factor: 14.808

Review 6.  Targeting inflammation in the treatment of type 2 diabetes: time to start.

Authors:  Marc Y Donath
Journal:  Nat Rev Drug Discov       Date:  2014-05-23       Impact factor: 84.694

7.  Exendin-4 increases islet amyloid deposition but offsets the resultant beta cell toxicity in human islet amyloid polypeptide transgenic mouse islets.

Authors:  K Aston-Mourney; R L Hull; S Zraika; J Udayasankar; S L Subramanian; S E Kahn
Journal:  Diabetologia       Date:  2011-04-12       Impact factor: 10.122

8.  Exenatide regulates pancreatic islet integrity and insulin sensitivity in the nonhuman primate baboon Papio hamadryas.

Authors:  Teresa Vanessa Fiorentino; Francesca Casiraghi; Alberto M Davalli; Giovanna Finzi; Stefano La Rosa; Paul B Higgins; Gregory A Abrahamian; Alessandro Marando; Fausto Sessa; Carla Perego; Rodolfo Guardado-Mendoza; Subhash Kamath; Andrea Ricotti; Paolo Fiorina; Giuseppe Daniele; Ana M Paez; Francesco Andreozzi; Raul A Bastarrachea; Anthony G Comuzzie; Amalia Gastaldelli; Alberto O Chavez; Eliana S Di Cairano; Patrice Frost; Livio Luzi; Edward J Dick; Glenn A Halff; Ralph A DeFronzo; Franco Folli
Journal:  JCI Insight       Date:  2019-10-17

Review 9.  The role of incretins in glucose homeostasis and diabetes treatment.

Authors:  Wook Kim; Josephine M Egan
Journal:  Pharmacol Rev       Date:  2008-12-12       Impact factor: 25.468

10.  Glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 modulate beta-cell chromatin structure.

Authors:  Su-Jin Kim; Cuilan Nian; Christopher H S McIntosh
Journal:  J Biol Chem       Date:  2009-03-11       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.